Test Price
450 AED✅ Home Collection Available
Newborn Screening Panel 8 Test in UAE – 450 AED
Executive Summary & Core Metrics
The Newborn Screening Panel 8 is a state-of-the-art biochemical assay designed to detect eight inborn errors of metabolism from a single heel-prick blood sample, ensuring early intervention and lifelong health for neonates in the UAE. Our DHA-licensed laboratory achieves 99.9% diagnostic sensitivity using ISO 9001:2015 certified processes.
⏱️ Turnaround Time
Next-day reporting (Mon/Wed/Fri)
🏠 Home Collection
VIP mobile phlebotomy 8 AM – 11 PM
📞 Clinical Support
Telephonic post-test consultation
Test Overview & Methodology
The panel uses a combination of Fluorescence Enzyme Immunoassay (FEIA), capillary electrophoresis, and LC-MS/MS confirmation to simultaneously screen for phenylketonuria, maple syrup urine disease, galactosemia, biotinidase deficiency, and hemoglobinopathies. The dried blood spot (DBS) sample is collected on pre-printed filter paper, refrigerated, and transported under strict cold-chain conditions to prevent degradation.
| Feature | Our Panel (DHA Certified) | Closest Alternative |
|---|---|---|
| Precision | 99.9% Diagnostic Sensitivity (ISO 9001:2015) | ~95% sensitivity, non-standardized |
| Methodology | FEIA + Capillary Electrophoresis (LC-MS/MS confirmation) | Semi-automated immunoassays |
| Turnaround | Next-day report (Mon/Wed/Fri) | 3–5 working days |
| Pre-test Requirements | Clinical history mandatory; cold-chain transport | Basic form, ambient transport |
Physician Insight & Safety Protocols
“Newborn screening is a cornerstone of preventive pediatric care. This panel identifies silent metabolic disorders before clinical symptoms appear, enabling timely intervention. Parents should always correlate results with their infant’s clinical presentation and consult our team for any ambiguity.”
— Dr. Ajay Singh, General Practitioner | DHA ID: 36234132
Medication & Clinical Advisory
Do not discontinue prescribed medication without consulting your doctor. Any changes to maternal or neonatal medication must be documented on the clinical history form accompanying the sample. If the infant is on total parenteral nutrition (TPN) or has had a recent blood transfusion, inform the laboratory immediately before collection.
Safety Exclusion Criteria & Emergency Red Flags
- Exclusion: Infants less than 24 hours of age (unreliable results); insufficient blood volume; missing clinical details or medication history.
- Do Not Collect/Submit: If the newborn is on TPN or recent blood transfusion, contact the lab for guidance. Samples must be collected by a trained professional only.
- Emergency Red Flags: If the infant exhibits lethargy, poor feeding, vomiting, hypothermia, or seizures, seek immediate emergency medical evaluation. This screening does not replace acute clinical care.
Patient FAQ & Clinical Guidance
1. What conditions does the Newborn Screening Panel 8 detect?
It screens for eight inborn errors of metabolism: phenylketonuria, maple syrup urine disease, galactosemia, biotinidase deficiency, and four hemoglobinopathies. Positive results are immediately communicated, and you will be referred to a pediatric metabolic specialist for confirmatory testing.
2. How is the sample collected and transported?
A small heel-prick blood sample is applied to three pre-printed filter paper spots, immediately refrigerated, and transported under strict cold-chain conditions. Our DHA-licensed mobile phlebotomist visits your home between 8 AM and 11 PM. Never freeze the sample—refrigeration at 2–8°C is mandatory until processing.
3. How quickly do I get the results and is insurance accepted?
Results are reported the next business day (Monday, Wednesday, or Friday) if the sample reaches our lab by 9 AM. We offer direct insurance billing verification via WhatsApp at +971 54 548 8731—simply share your insurance card and our team confirms coverage within minutes. The PDF report is delivered electronically with a telephonic consultation.
UAE Regulatory & Data Privacy Adherence
This service strictly complies with:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL)
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields
- Federal Decree-Law No. 4 of 2016 on Medical Liability (patient safety and consent)
Laboratory operates under DHA Facility License No. 1143. All patient data is encrypted and processed in accordance with UAE health data governance standards.
Clinical & Logistical Metadata
| Test Name | Newborn Screening Panel 8 |
| Price (AED) | 450 AED |
| Turnaround Time | 24-48 hours (next business day after sample receipt) |
| Sample Type / Matrix | Heel-prick capillary blood on filter paper (Dried Blood Spot) |
| Methodology Used | FEIA + Capillary Electrophoresis + LC-MS/MS confirmation |
| ICD-10-CM Code | Z13.228 |
| LOINC Code | 57712-8 |
| DHA Facility License & Laboratory Address | DHA License: 1143 | DNA Labs UAE Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians